Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery-A Humanitarian Cause

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Dec 17

PMID 39684504

Authors

Sarfaraz K Niazi

Matthias Magoola

Affiliations

Soon will be listed here.

Abstract

Recombinant therapeutic and vaccine proteins have revolutionized healthcare, but there remain challenges, as many are awaiting development due to their slow development speed and high development cost. Cell-free in vivo ribosomes offer one choice, but they come with similar constraints. The validation of in vivo messenger RNA (mRNA) technology has been accomplished for COVID-19 vaccines. The bioreactors inside the body, the ribosomes, deliver these proteins at a small cost, since these are chemical products and do not require extensive analytical and regulatory exercises. In this study, we test and validate the final product. A smaller fraction of the recombinant protein cost is needed, removing both constraints. Although thousands of in vivo mRNA products are under development, their regulatory classification remains unresolved: do they qualify as chemical drugs, biological drug, or gene therapy items? These questions will soon be resolved. Additionally, how would the copies of approved in vivo mRNA protein products be brought in, and how would they be treated: as new drugs, generic drugs, or new biological drugs? Researchers are currently working to answer these questions. Regardless, these products' cost of goods (COGs) remains much smaller than that of ex vivo mRNA or recombinant products. This is necessary to meet the needs of the approximately 6.5 billion people around the world who do not have access to biological drugs; these products will indeed serve the dire needs of humanity. Given the minor cost of establishing the manufacturing of these products, it will also prove financially attractive to investors.

References

Caschera F, Noireaux V . Synthesis of 2.3 mg/ml of protein with an all Escherichia coli cell-free transcription-translation system. Biochimie. 2013; 99:162-8. DOI: 10.1016/j.biochi.2013.11.025. View

Hodgman C, Jewett M . Cell-free synthetic biology: thinking outside the cell. Metab Eng. 2011; 14(3):261-9. PMC: 3322310. DOI: 10.1016/j.ymben.2011.09.002. View

Jackson D, Symons R, Berg P . Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci U S A. 1972; 69(10):2904-9. PMC: 389671. DOI: 10.1073/pnas.69.10.2904. View

Meselson M, Stahl F . THE REPLICATION OF DNA IN ESCHERICHIA COLI. Proc Natl Acad Sci U S A. 1958; 44(7):671-82. PMC: 528642. DOI: 10.1073/pnas.44.7.671. View

Schlake T, Thess A, Fotin-Mleczek M, Kallen K . Developing mRNA-vaccine technologies. RNA Biol. 2012; 9(11):1319-30. PMC: 3597572. DOI: 10.4161/rna.22269. View

Berg P, Mertz J . Personal reflections on the origins and emergence of recombinant DNA technology. Genetics. 2010; 184(1):9-17. PMC: 2815933. DOI: 10.1534/genetics.109.112144. View

Bergman S, Ferguson M, Santanello C . Interferons as therapeutic agents for infectious diseases. Infect Dis Clin North Am. 2011; 25(4):819-34. PMC: 7134994. DOI: 10.1016/j.idc.2011.07.008. View

PAULING L, Corey R, BRANSON H . The structure of proteins; two hydrogen-bonded helical configurations of the polypeptide chain. Proc Natl Acad Sci U S A. 1951; 37(4):205-11. PMC: 1063337. DOI: 10.1073/pnas.37.4.205. View

Pardi N, Hogan M, Porter F, Weissman D . mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4):261-279. PMC: 5906799. DOI: 10.1038/nrd.2017.243. View

10.

Hughes S . Making dollars out of DNA. The first major patent in biotechnology and the commercialization of molecular biology, 1974-1980. Isis. 2002; 92(3):541-75. DOI: 10.1086/385281. View

11.

Niazi S . Biosimilars Adoption: Recognizing and Removing the RoadBlocks. Clinicoecon Outcomes Res. 2023; 15:281-294. PMC: 10106314. DOI: 10.2147/CEOR.S404175. View

12.

Requena J . The protean prion protein. PLoS Biol. 2020; 18(6):e3000754. PMC: 7316225. DOI: 10.1371/journal.pbio.3000754. View

13.

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

14.

SZMUNESS W, Stevens C, Harley E, Zang E, Oleszko W, William D . Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980; 303(15):833-41. DOI: 10.1056/NEJM198010093031501. View

15.

Ayyar V . History of growth hormone therapy. Indian J Endocrinol Metab. 2011; 15 Suppl 3:S162-5. PMC: 3183530. DOI: 10.4103/2230-8210.84852. View

16.

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

17.

Forster A, Church G . Towards synthesis of a minimal cell. Mol Syst Biol. 2006; 2:45. PMC: 1681520. DOI: 10.1038/msb4100090. View

18.

Niazi S . The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars. Pharmaceuticals (Basel). 2023; 16(11). PMC: 10674418. DOI: 10.3390/ph16111517. View

19.

Mannucci P, Tuddenham E . The hemophilias--from royal genes to gene therapy. N Engl J Med. 2001; 344(23):1773-9. DOI: 10.1056/NEJM200106073442307. View

20.

Rathore A, Gardner P, Chhabra H, Raman R . Global outlook on affordability of biotherapeutic drugs. Ann N Y Acad Sci. 2024; 1537(1):168-178. DOI: 10.1111/nyas.15171. View